Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
The hour's top business headlines, with CNBC's Mike Huckman.
CNBC's Mike Huckman has the hour's business news headlines.
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

PHARMA'S MARKET VIDEO

» More

Current DateTime: 09:19:20 10 Jul 2009
LinksList Documentid: 31171988
Expiration DateTime: 7/10/2009 9:21:08 AM

RSS FEED

» Help

Current DateTime: 09:19:21 10 Jul 2009
LinksList Documentid: 31171995
Pharma's Market Blog
Text Size
Jul.26
11:35 AM ET
Thursday, 26 Jul 2007
GlaxoSmith And FDA: Will Avandia Get A Clean Bill of Health?

I think I just killed a tree. This morning I printed out the GlaxoSmithKline [GSK  Loading...      ()   ] and FDA documents that were posted on the agency's Web site ahead of the advisory committee meeting on Avandia safety next Monday. About 700 pages! Nearly as many pages as the new "Harry Potter" book, but not nearly as entertaining.

Actually, I bought the 'Potter' book on CD and haven't started listening to it yet (The narrator, Broadway veteran Jim Dale, by the way, is incredible. Don't know how he does it, but he slips from one character's voice into the next.) I digress. Contained within the documents are the results of a new GSK study (I wonder how much it cost) of the health insurance records of 400,000 diabetics that apparently show Avandia carries no greater heart attack risk than other diabetes drugs. We'll find out on Monday how much weight that carries with the huge panel.

Click for related content

The FDA has put nearly two dozen voting members on the committee for this meeting. The typical panel usually has around eight or 10. Now that the makeup of the committee is public, analysts will be busy checking out each member and trying to predict which way they might vote. At least a couple of senators claim the group is stacked in GSK's favor. The FDA staff's documents say the agency has "considerable concern" about the potential heart attack risk with Avandia, but adds that there are "somewhat inconsistent findings" regarding that risk.

The panel will hear from both sides Monday and then in the late afternoon vote on recommendations that could possibly result in a severe safety warning being put on the Avandia label or maybe even the drug being ordered off the market.

If you want some good bedtime reading go to www.fda.gov. Click on Advisory Committees, then Drugs and then on the Endocrinologic and Metabolic Drugs "Go" tab and you, too, can wipe out a forest.

Questions?  Comments? 
© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon


Current DateTime: 08:26:52 10 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:09 10 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 07:29:15 10 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:05:34 10 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters